Lung Cancer Stem Cells and Implications for Future Therapeutics

Cell Biochemistry and Biophysics

Volumn 69, Issue 3, 2014, Pages 389-398

  Wang, Jing ^a   Li, Ze hong ^a   White, James ^b   Zhang, Lin bo ^a  

^a JILIN AGRICULTURAL UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ABCG2 (ATP binding cassette sub family G member 2); ALDH (aldehyde dehydrogenase); Cancer stem cells (CSCs); CD133; CD44; Lung cancer

Indexed keywords

ERINACEIDAE;

TUMOR MARKER;

CANCER STEM CELL; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84902376586     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9844-4     Document Type: Review

References (112)

1. Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. New England Journal of Medicine, 359, 1367-1380.
2. Martel, C., Ferlay, J., Franceschi, S., et al. (2012). Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology, 13, 607-615.
3. American Cancer Society. (2011). Cancer facts & figures 2011. Atlanta: American Cancer Society.
4. Brodowicz, T., Ciuleanu, T., Crawford, J., et al. (2012). Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology, 23, 1223-1229.
5. D'Addario, G., & Felip, E. (2009). ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20, 68-70.
6. D'Addario, G., Früh, M., Reck, M., et al. (2010). Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21, 116-119.
7. Goldstraw, P., Ball, D., Jett, J. R., et al. (2011). Non-small-cell lung cancer. Lancet, 378, 1727-1740.
8. Travis, W. D., Travis, L. B., & Devesa, S. S. (1995). Lung cancer. Cancer, 75, 191-202.
9. Alison, M. R., Lin, W. R., Lim, S. M., et al. (2012). Cancer stem cells: in the line of fire. Cancer Treatment Reviews, 38, 589-598.
10. Mani, S. A., Guo, W., Liao, M. J., et al. (2008). The epithelial mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715.
11. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730-737.
12. Korkaya, H., & Wicha, M. S. (2007). Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs, 21, 299-310.
13. Perona, R., Lopez-Ayllon, B. D., de Castro Carpeno, J., et al. (2011). A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clinical and Translational Oncology, 13, 289-293.
14. Li, J., & Zhou, B. P. (2011). Activation of beta-catenin and Akt pathways by twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer, 11, 49.
15. Kelsey, C. R., Marks, L. B., Hollis, D., et al. (2009). Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. Cancer, 115, 5218-5227.
16. Wisnivesky, J. P., Yankelevitz, D., & Henschke, C. I. (2005). Stage of lung cancer in relation to its size: Part 2. Evidence. Chest, 127, 1136-1139.
17. Howlader, N., Noon, A. M., Krapcho, M., et al. (2012). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. http://seer. cancer. gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER website, April 2012.
18. Pao, W., Miller, V. A., Politi, K. A., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine, 2, e73.
19. Katayama, R., Shaw, A. T., Khan, T. M., et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Science Translational Medicine, 4, 120ra17.
20. Janne, P. A., Freidlin, B., Saxman, S., et al. (2002). Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer, 95, 1528-1538.
21. Murray, N., Coy, P., Pater, J. L., et al. (1993). Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 11, 336-344.
22. Lapidot, T., Sirard, C., Vormoor, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-648.
23. Rivera, C., Rivera, S., Loriot, Y., et al. (2011). Lung cancer stem cell: New insights on experimental models and preclinical data. Journal of Oncology, 2011, 549181.
24. O'Flaherty, J. D., Barr, M., Fennell, D., et al. (2012). The cancer stem-cell hypothesis: Its emerging role in lung cancer biology and its relevance for future therapy. Journal of Thoracic Oncology, 7, 1880-1890.
25. Eyler, C. E., & Rich, J. N. (2008). Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology, 26, 2839-2845.
26. Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews Cancer, 8, 755-768.
27. Visvader, J. E., & Lindeman, G. J. (2012). Cancer stem cells: Current status and evolving complexities. Cell Stem Cell, 10, 717-728.
28. Welte, Y., Adjaye, J., Lehrach, H. R., et al. (2010). Cancer stem cells in solid tumors: Elusive or illusive? Cell Communication and Signaling, 8, 6.
29. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., et al. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983-3988.
30. Garvalov, B. K., & Acker, T. (2011). Cancer stem cells: A new framework for the design of tumor therapies. Journal of Molecular Medicine (Berlin), 89, 95-107.
31. Lundin, A., & Driscoll, B. (2013). Lung cancer stem cells: Progress and prospects. Cancer Letters, 338, 89-93.
32. He, S., Nakada, D., & Morrison, S. J. (2009). Mechanisms of stem cell self-renewal. Annual Review of Cell and Developmental Biology, 25, 377-406.
33. Eramo, A., Lotti, F., Sette, G., et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 15, 504-514.
34. Bertolini, G., Roz, L., Perego, P., et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America, 106, 16281-16286.
35. Chen, Y. C., Hsu, H. S., Chen, Y. W., et al. (2008). Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One, 3, e2637.
36. Meng, X., Li, M., Wang, X., et al. (2009). Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Science, 100, 1040-1046.
37. Salcido, C. D., Larochelle, A., Taylor, B. J., et al. (2010). Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. British Journal of Cancer, 102, 1636-1644.
38. Ho, M. M., Ng, A. V., Lam, S., et al. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67, 4827-4833.
39. Gutova, M., Najbauer, J., Gevorgyan, A., et al. (2007). Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One, 2, e243.
40. Cui, F., Wang, J., Chen, D., et al. (2011). CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncology Reports, 25, 701-708.
41. Akunuru, S., James Zhai, Q., & Zheng, Y. (2012). Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death and Disease, 3, e352.
42. Niu, Q., Wang, W., Li, Y., et al. (2012). Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation. PLoS One, 7, e41035.
43. Shi, Y., Fu, X., Hua, Y., et al. (2012). The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS One, 7, e33358.
44. Wang, F., Mi, Y. J., Chen, X. G., et al. (2012). Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Molecular Medicine, 18, 887-898.
45. Nakatsugawa, M., Takahashi, A., Hirohashi, Y., et al. (2011). SOX2 is overexpressed in stemlike cells of human lung adenocarcinoma and augments the tumorigenicity. Laboratory Investigation, 91, 1796-1804.
46. Liang, D., & Shi, Y. (2012). Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Medical Oncology, 29, 633-639.
47. Sullivan, J. P., Spinola, M., Dodge, M., et al. (2010). Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Research, 70, 9937-9948.
48. Kubo, T., Takigawa, N., Osawa, M., et al. (2013). Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Science, 104, 78-84.
49. Hegedus, C., Truta-Feles, K., Antalffy, G., et al. (2012). Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochemical Pharmacology, 84, 260-267.
50. Sung, J. M., Cho, H. J., Yi, H., et al. (2008). Characterization of a stem cell population in lung cancer A549 cells. Biochemical and Biophysical Research Communications, 371, 163-167.
51. Meng, X., Wang, X., & Wang, Y. (2009). More than 45 % of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses. Oncology Reports, 21, 995-1000.
52. Zhou, J., Wang, H., Cannon, V., et al. (2011). Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. Molecular Cancer, 10, 112.
53. Shmelkov, S. V., Butler, J. M., Hooper, A. T., et al. (2008). CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. Journal of Clinical Investigation, 118, 2111-2120.
54. Jaggupilli, A., & Elkord, E. (2012). Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clinical and Developmental Immunology, 2012, 708036.
55. Du, L., Wang, H., He, L., et al. (2008). CD44 is of functional importance for colorectal cancer stem cells. Clinical Cancer Research, 14, 6751-6760.
56. Bapat, S. A. (2010). Human ovarian cancer stem cells. Reproduction, 140, 33-41.
57. Lee, H. J., Choe, G., Jheon, S., et al. (2010). CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: A retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. Journal of Thoracic Oncology, 5, 649-657.
58. Slomiany, M. G., Dai, L., Tolliver, L. B., et al. (2009). Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clinical Cancer Research, 15, 7593-7601.
59. Leung, E. L., Fiscus, R. R., Tung, J. W., et al. (2010). Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One, 5, e14062.
60. An, Y., & Ongkeko, W. M. (2009). ABCG2: The key to chemoresistance in cancer stem cells? Expert Opinion on Drug Metabolism and Toxicology, 5, 1529-1542.
61. Ross, D. D., & Nakanishi, T. (2010). Impact of breast cancer resistance protein on cancer treatment outcomes. Methods in Molecular Biology, 596, 251-290.
62. Krishnamurthy, P., Ross, D. D., Nakanishi, T., et al. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. Journal of Biological Chemistry, 279, 24218-24225.
63. Ahmed, F., Arseni, N., Glimm, H., et al. (2008). Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells, 26, 810-818.
64. Levina, V., Marrangoni, A. M., & De Marco, R. (2008). Drugselected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS One, 3, e3077.
65. Rosner, M. H., Vigano, M. A., Ozato, K., et al. (1990). A POUdomain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature, 345, 686-692.
66. Hilbe, W., Dirnhofer, S., Oberwasserlechner, F., et al. (2004). CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. Journal of Clinical Pathology, 57, 965-969.
67. Herpel, E., Jensen, K., Muley, T., et al. (2011). The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Research, 31, 4491-4500.
68. Russo, J. E., & Hilton, J. (1998). Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Research, 48, 2963-2968.
69. Huang, C. P., Tsai, M. F., Chang, T. H., et al. (2013). ALDH positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters, 328, 144-151.
70. Lu, Y., Thomson, J. M., Wong, H. Y., et al. (2007). Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Development Biology, 310, 442-453.
71. Karamboulas, C., & Ailles, L. (2013). Developmental signaling pathways in cancer stem cells of solid tumors. Biochimica et Biophysica Acta, 1830, 2481-2495.
72. Takebe, N., & Ivy, S. P. (2010). Controversies in cancer stem cells: targeting embryonic signaling pathways. Clinical Cancer Research, 16, 3106-3112.
73. Varjosalo, M., & Taipale, J. (2008). Hedgehog: Functions and mechanisms. Genes and Development, 22, 2454-2472.
74. Sasaki, H., Nishizaki, Y., Hui, C., et al. (1999). Regulation of GLI2 and GLI3 activities by an amino-terminal repression domain: Implication of GLI2 and GLI3 as primary mediators of Shh signaling. Development, 126, 3915-3924.
75. Clement, V., Sanchez, P., de Tribolet, N., et al. (2007). HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell selfrenewal, and tumorigenicity. Current Biology, 17, 165-172.
76. Peacock, C. D., Wang, Q., Gesell, G. S., et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104, 4048-4053.
77. Stecca, B., Mas, C., Clement, V., et al. (2007). Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proceedings of the National Academy of Sciences of the United States of America, 104, 5895-5900.
78. Mukherjee, S., Frolova, N., Sadlonova, A., et al. (2006). Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biology and Therapy, 5, 674-683.
79. Yuan, Z., Goetz, J. A., Singh, S., et al. (2007). Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene, 26, 1046-1055.
80. Watkins, D. N., Berman, D. M., Burkholder, S. G., et al. (2003). Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature, 422, 313-317.
81. Park, K. S., Martelotto, L. G., Peifer, M., et al. (2011). A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine, 17, 1504-1508.
82. Collins, B. J., Kleeberger, W., & Ball, D. W. (2004). Notch in lung development and lung cancer. Seminars in Cancer Biology, 14, 357-364.
83. Richter, S., McWhirter, E., Chen, E. X., et al. (2012). A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine, in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology, 30, 3082.
84. Ito, T., Udaka, N., Yazawa, T., et al. (2000). Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development, 127, 3913-3921.
85. Dang, T. P., Eichenberger, S., Gonzalez, A., et al. (2003). Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene, 22, 1988-1997.
86. Chen, H., Thiagalingam, A., Chopra, H., et al. (1997). Conservation of the Drosophila lateral inhibition pathway in human lung cancer: A hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proceedings of the National Academy of Sciences of the United States of America, 94, 5355-5360.
87. Osanyingbemi-Obidi, J., Dobromilskaya, I., Illei, P. B., et al. (2011). Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Molecular Cancer Research, 9, 1746-1754.
88. Konishi, J., Kawaguchi, K. S., Vo, H., et al. (2007). Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Research, 67, 8051-8057.
89. Weijzen, S., Rizzo, P., Braid, M., et al. (2002). Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine, 8, 979-986.
90. Westhoff, B., Colaluca, I. N., D'Ario, G., et al. (2009). Alterations of the Notch pathway in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 106, 22293-22298.
91. Nicolas, M., Wolfer, A., Raj, K., et al. (2003). Notch1 functions as a tumor suppressor in mouse skin. Nature Genetics, 33, 416-421.
92. Klinakis, A., Lobry, C., Abdel-Wahab, O., et al. (2011). A novel tumour suppressor function for the Notch pathway in myeloid leukaemia. Nature, 473, 230-233.
93. Liu, Z., Turkoz, A., Jackson, E. N., et al. (2011). Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. Journal of Clinical Investigation, 121, 800-808.
94. Phng, L. K., & Gerhardt, H. (2009). Angiogenesis: A team effort coordinated by Notch. Developmental Cell, 16, 196-208.
95. Radtke, F., Fasnacht, N., & Macdonald, H. R. (2010). Notch signaling in the immune system. Immunity, 32, 14-27.
96. Willert, K., & Jones, K. A. (2006). Wnt signaling: Is the party in the nucleus? Genes and Development, 20, 1394-1404.
97. He, B., Barg, R. N., You, L., et al. (2005). Wnt signaling in stem cells and non-small-cell lung cancer. Clinical Lung Cancer, 7, 54-60.
98. Uematsu, K., He, B., You, L., et al. (2003). Activation of the Wnt pathway in non small cell lung cancer: Evidence of dishevelled overexpression. Oncogene, 22, 7218-7221.
99. Teng, Y., Wang, X., Wang, Y., et al. (2010). Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochemical and Biophysical Research Communications, 392, 373-379.
100. Yeh, C. T., Wu, A. T., Chang, P. M., et al. (2012). Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. American Journal of Respiratory and Critical Care Medicine, 186, 1180-1188.
101. Serrano, D., Bleau, A. M., Fernandez-Garcia, I., et al. (2011). Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Molecular Cancer, 10, 96.
102. He, B., You, L., Uematsu, K., et al. (2004). A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia, 6, 7-14.
103. Tian, F., Mysliwietz, J., Ellwart, J., et al. (2012). Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. Clinical and Experimental Medicine, 12, 25-30.
104. Levina, V., Marrangoni, A., Wang, T., et al. (2010). Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Research, 70, 338-346.
105. Hill, R. P. (2006). Identifying cancer stem cells in solid tumors: Case not proven. Cancer Research, 66, 1891-1895.
106. Kern, S. E., & Shibata, D. (2007). The fuzzy math of solid tumor stem cells: A perspective. Cancer Research, 67, 8985-8988.
107. Kelly, P. N., Dakic, A., Adams, J. M., et al. (2007). Tumor growth need not be driven by rare cancer stem cells. Science, 317, 337.
108. Quintana, E., Shackleton, M., Sabel, M. S., et al. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456, 593-598.
109. Li, Z., Bao, S., Wu, Q., et al. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15, 501-513.
110. Heddleston, J. M., Li, Z., McLendon, R. E., et al. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle, 8, 3274-3284.
111. Li, L., & Neaves, W. B. (2006). Normal stem cells and cancer stem cells: The niche matters. Cancer Research, 66, 4553-4557.
112. Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells: Mirage or reality? Nature Medicine, 15, 1010-1012.